1. PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia
   Hui Cheng et al, 2017, J Transl Med CrossRef
2. Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors
   Bassem H. Naguib et al, 2017, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
3. A Systematic Analysis of the Binding Affinity between the Pim-1 Kinase and Its Inhibitors Based on the MM/3D-RISM/KH Method
   Takeshi Hasegawa et al, 2017, J. Chem. Inf. Model. CrossRef
4. Synthesis of new pyridothienopyrimidinone and pyridothienotriazolopyrimidine derivatives as pim-1 inhibitors
   Hala B. El-Nassan et al, 2018, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
5. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
   Aziz Aziz et al, 2018, Biomolecules CrossRef
6. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases
   K. Chojnacki et al, 2018, Bioorganic Chemistry CrossRef
7. How is structural divergence related to evolutionary information?
   Diego Javier Zea et al, 2018, Molecular Phylogenetics and Evolution CrossRef
8. STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells
   Daniel Ribeiro et al, 2018, Blood Adv CrossRef
9. PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes
   You-Jung Ha et al, 2018 CrossRef
10. Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer
    A. Fucic et al, 2018, Pathol. Oncol. Res. CrossRef
11. Regulation of insulin resistance and glucose metabolism by interaction of PIM kinases and insulin receptor substrates
    Aziz ur Rehman Aziz et al, 2018, Archives of Physiology and Biochemistry CrossRef
12. Revealing quinquennial anticancer journey of morpholine: A SAR based review
    Fatima Arshad et al, 2019, European Journal of Medicinal Chemistry CrossRef
13. Site-Specific Cleavage of RNAs Derived from the PIM1 3′-UTR by a Metal-Free Artificial Ribonuclease
    Felix Zellmann et al, 2019, Molecules CrossRef
14. In Vitro and In Vivo Anti-Breast Cancer Activities of Some Newly Synthesized 5-(thiophen-2-yl)thieno-[2,3-d]pyrimidin-4-one Candidates
    Abd El-Galil E. Amr et al, 2019, Molecules CrossRef
15. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations
    Maiara Bernardes Marques et al, 2019, CTMC CrossRef
16. Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel
    Aaron R. Tipton et al, 2016, Biochemical and Biophysical Research Communications CrossRef
17. Doxorubicin-induced toxicity to 3D-cultured rat ovarian follicles on a microfluidic chip
    Aziz ur Rehman Aziz et al, 2019, Toxicology in Vitro CrossRef
18. Sevoflurane pretreatment attenuates hypoxia/reoxygenation-induced cardiomyocyte apoptosis through activation of AKT/pim-1 and AKT/GSK3β signaling pathways
    Wensheng Zhao et al, 2019, Biotechnology & Biotechnological Equipment CrossRef
19. Identification of target associations for polypharmacology from analysis of crystallographic ligands of the Protein Data Bank
    Luca Pinzi et al, 2019, J. Chem. Inf. Model. CrossRef
20. Apoptosis: A Target for Anticancer Therapy with Novel Cyanopyridines
    Magda M.F. Ismail et al, 2019, Bioorganic Chemistry CrossRef
21. Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer
    Tom Malone et al, 2019, Pharmacology & Therapeutics CrossRef
22. Synthesis of new oxadiazol-phthalazinone derivatives with anti-proliferative activity; molecular docking, pro-apoptotic, and enzyme inhibition profile
    Mohamed H. Hekal et al, 2020, RSC Adv. CrossRef
23. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer
    Sabina Luszczak et al, 2020, Sig Transduct Target Ther CrossRef
24. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
    Sean P. Kennedy et al, 2020, Oncogene CrossRef
25. A new method for estimating the relative binding free energy, derived from a free energy variational principle for the Pim-1-kinase–ligand and FKBP–ligand systems
    Takeshi Ashida et al, 2020, J Comput Aided Mol Des CrossRef
26. New pyrazolopyrimidine derivatives with anticancer activity: Design, synthesis, PIM-1 inhibition, molecular docking study and molecular dynamics
    John N. Philoppes et al, 2020, Bioorganic Chemistry CrossRef
27. PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients
    Athina Markou et al, 2020, Cancers CrossRef
28. Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
    Anantha N. Nagappa et al, 2020, CEI CrossRef
29. Reduced pim‑1 expression increases chemotherapeutic drug sensitivity in human androgen‑independent prostate cancer cells by inducing apoptosis
    Xing Zhang et al, 2019, Exp Ther Med CrossRef
30. Synthesis, anticancer screening, and in silico ADME prediction of novel 2‐pyridones as Pim inhibitors
    Magda M. F. Ismail et al, 2020, J Heterocyclic Chem CrossRef
31. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
    Motoki Eguchi et al, 2020, Biomedicines CrossRef
32. null
    Akerke Altaikyzy et al, 2018 CrossRef
33. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
    Sabina Luszczak et al, 2020, Sci Rep CrossRef
34. New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study
    Amel M. Farrag et al, 2020, Bioorganic Chemistry CrossRef
35. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells
    Mohamed S. Nafie et al, 2020, Bioorganic & Medicinal Chemistry CrossRef
36. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development
    Charles E. de Bock et al, 2018, Cancer Discov CrossRef
37. Molecular Recognition and Self-Organization in Life Phenomena Studied by a Statistical Mechanics of Molecular Liquids, the RISM/3D-RISM Theory
    Masatake Sugita et al, 2021, Molecules CrossRef
38. miR24–3p activity after delivery into pancreatic carcinoma cell lines exerts profound tumor-inhibitory effects through distinct pathways of apoptosis and autophagy induction
    Hannes Borchardt et al, 2021, Cancer Letters CrossRef
39. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation
    Bruno Oyallon et al, 2021, Molecules CrossRef
40. New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells.
    Eva Schaller et al, 2021, Int J Mol Sci CrossRef
41. Remodelling structure-based drug design using machine learning
    Shubhankar Dutta et al, 2021 CrossRef
42. Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC.
    Gillian Moore et al, 2021, Cancers (Basel) CrossRef
43. In vitro assessment of the efficiency of the PIM‑1 kinase pharmacological inhibitor as a potential treatment for Burkitt's lymphoma
    Mona Alsubaie et al, 2021, Oncol Lett CrossRef
44. The Potential Role of RP105 in Regulation of Inflammation and Osteoclastogenesis During Inflammatory Diseases
    Zhou Fan et al, 2021, Front. Cell Dev. Biol. CrossRef
45. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects
    Aanchal Rathi et al, 2021, Biochimica et Biophysica Acta (BBA) - General Subjects CrossRef
46. Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases
    Viet Hung Dao et al, 2021, Molecules CrossRef
47. A review of FLT3 inhibitors in acute myeloid leukemia
    Jennifer Zhao et al, 2021, Blood Reviews CrossRef
48. A systematic review on active sites and functions of PIM-1 protein
    Youyi Zhao et al, 2022, Human Cell CrossRef
49. TARGETTING THE 3BGQ - PIM1 KINASE INTERACTION WITH A SERIES OF NOVEL DITHIOCARBAMATE SUBSTITUTED 2-OXOINDOLE DERIVATIVES- IN SILICO STUDIES
    Saritha Jyostna TANGEDA et al, 2022 CrossRef
50. Bio-physical and Computational Studies on Serum Albumin / Target Protein Binding of a Potential Anti-Cancer Agent
    Sreedhanya SreedharanNair et al, 2022, European Journal of Pharmaceutical Sciences CrossRef
51. A candidate triple-negative breast cancer vaccine design by targeting clinically relevant cell surface markers: an integrated immuno and bio-informatics approach
    Shashank Kumar et al, 2022, 3 Biotech CrossRef
52. In-silico and in-vitro investigation of STAT3-PIM1 heterodimeric complex: Its mechanism and inhibition by curcumin for cancer therapeutics
    Sutapa Mahata et al, 2022, International Journal of Biological Macromolecules CrossRef
53. Molecular mechanisms of drug resistance of glioblastoma. Part 1: ABC family proteins and inhibitors
    Alexander N. Chernov et al, 2021, Medical academic journal CrossRef
54. Synthesis and Antiproliferative Activity of 2-oxo-1,2-dihydropyridine-3,4-dicarbonitriles
    S. V. Fedoseev et al, 2022, Pharm Chem J CrossRef
55. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
    Yun Liu et al, 2022, J Hematol Oncol CrossRef
56. Clinical Significance of Pim-1 in Human Cancers: A Meta-analysis of Association with Prognosis and Clinicopathological Characteristics
    Lin Lai et al, 2022, Cancer Control CrossRef
57. Discovery of novel natural products as dual MNK/PIM inhibitors for acute myeloid leukemia treatment: Pharmacophore modeling, molecular docking, and molecular dynamics studies
    Linda M. Mohamed et al, 2022, Front. Chem. CrossRef
58. Design, Synthesis, Molecular Docking, and Biological Studies of New Heterocyclic Compounds Derived from β-Diketones as Novel EGFR and Pim-1 Inhibitors Endowed with Antitumor Activity
    Rafat Milad Mohareb et al, 2022, ACAMC CrossRef
59. Development of novel cyanopyridines as PIM-1 kinase inhibitors with potent anti-prostate cancer activity: Synthesis, biological evaluation, nanoparticles formulation and molecular dynamics simulation
    Mona H. Ibrahim et al, 2022, Bioorganic Chemistry CrossRef
60. Antitumor activity of the protein kinase inhibitor 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines
    Mirosława Koronkiewicz et al, 2022, BMC Cancer CrossRef
61. The AHR target gene scinderin activates the WNT pathway by facilitating the nuclear translocation of β-catenin
    Lizbeth Perez-Castro et al, 2022 CrossRef
62. Pim1 promotes IFN-β production by interacting with IRF3
    Ryeojin Ko et al, 2022, Exp Mol Med CrossRef
63. Mesenchymal Cells in The Lung: Evolving Concepts and Their Role in Fibrosis
    Giovanni Ligresti et al, 2023, Gene CrossRef
64. Hinged Bipodal Furoylthiourea-Based Ru(II)-Arene Complexes: Effect of (ortho, meta, or para)-Substitution on Coordination and Anticancer Activity
    Srividya Swaminathan et al, 2023, Inorg. Chem. CrossRef
65. Discovery of PIM-1 kinase inhibitors based on the 2,5-disubstituted 1,3,4-oxadiazole scaffold against prostate cancer: Design, synthesis, in vitro and in vivo cytotoxicity investigation
    Anne-Sophie Castanet et al, 2023, European Journal of Medicinal Chemistry CrossRef
66. Combining machine learning and structure-based approaches to develop oncogene PIM kinase inhibitors
    Haifa Almukadi et al, 2023, Front. Chem. CrossRef
67. A PIM-1 Kinase Inhibitor Docking Optimization Study Based on Logistic Regression Models and Interaction Analysis
    George Nicolae Daniel Ion et al, 2023, Life CrossRef
68. Multifunctional Theranostic Probe Based on the Pim-1 Kinase Inhibitor with the Function of Tracking pH Fluctuations during Treatment
    Caiyun Liu et al, 2023, Anal. Chem. CrossRef
69. Targeting Stem Cells and Dysplastic Features with Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis
    Hyesung Kim et al, 2023, Gastroenterology CrossRef
70. Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer
    Yoon Sun Park et al, 2023, Cancer Biology & Therapy CrossRef
71. Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles
    Li Chen et al, 2024, J. Med. Chem. CrossRef
72. Screening of Biomarkers Associated with Osteoarthritis Aging Genes and Immune Correlation Studies
    Lanwei Xu et al, 2024, IJGM CrossRef
73. Exploring the Potential of Baicalin and Resveratrol as PIM-1 Kinase Inhibitors: Therapeutic Targeting of Prostate and Breast Cancers
    Aanchal Rathi et al, 2024, Journal of Molecular Liquids CrossRef
74. Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
    Qianqian Xu et al, 2024, Neoplasia CrossRef
75. Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer
    Anushka Sharma et al, 2024, Mol Divers CrossRef
76. Deciphering the cross-talk between miRNA and tight junctions in hepatocellular carcinoma
    Siva Bala Subramaniya et al, 2024, Explor Dig Dis CrossRef
77. PIM kinase inhibitors: an updated patent review (2016-present)
    Anushka Sharma et al, 2024, Expert Opinion on Therapeutic Patents CrossRef
78. The role of Pim-1 kinases in inflammatory signaling pathways
    Hye Suk Baek et al, 2024, Inflamm. Res. CrossRef
79. Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3-b]pyridazine derivatives as dual c-Met/Pim-1 potential inhibitors with antitumor activity
    Mohamed E. Mahmoud et al, 2024, RSC Adv. CrossRef
80. An experimental and computational investigation of the cyclopentene-containing peptide-derived compounds: focus on pseudo-cyclic motifs via intramolecular interactions
    Joanna Bojarska et al, 2024, R. Soc. Open Sci. CrossRef
81. Comparative in Silico study of apigenin and its dimeric forms on PIM1 kinase in glioblastoma multiform
    Mohammad-Sadegh Lotfi et al, 2024, Computational Biology and Chemistry CrossRef
82. Design, synthesis, and anti-breast cancer activity evaluation of novel 3-cyanopyridine derivatives as PIM-1 inhibitors
    Bahgat R. M. Hussein et al, 2024, Mol Divers CrossRef
83. Exploring 7β-amino-6-nitrocholestens as COVID-19 antivirals: in silico, synthesis, evaluation, and integration of artificial intelligence (AI) in drug design: assessing the cytotoxicity and antioxidant activity of 3β-acetoxynitrocholestane
    null Shahabuddin et al, 2024, RSC Med. Chem. CrossRef
84. PIM Kinase Inhibitors as Novel Promising Therapeutic Scaffolds in Cancer Therapy
    Dipanjan Karati et al, 2024, CTMC CrossRef
85. Effect of hinokitiol in ameliorating oral cancer: in vitro and in silico evidences
    Anitha Roy et al, 2024, Odontology CrossRef
86. Investigational drugs in early phase trials for myelofibrosis
    Sankalp Arora et al, 2024, Expert Opinion on Investigational Drugs CrossRef
87. Emerging Trends in Quinoxaline‐Based Analogs as Protein Kinase Inhibitors: Structural Developments and SAR Insights
    null Shivani et al, 2024, ChemMedChem CrossRef
88. PIM1 enhances insulin secretion and inhibits ferroptosis of high glucose-induced pancreatic β-cells through strengthening PINK1/Parkin-mediated mitophagy via inactivating JNK/p38 signaling pathway
    Bingjie Fan et al, 2025, Tissue and Cell CrossRef